Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2026)
Protagonist Therapeutics (PTGX) posted Operating Leases of $7.4 million for Q1 2026, down 7.5% sequentially from $8.0 million in Q4 2025, and down 24.05% YoY from $9.8 million in Q1 2025.
Protagonist Therapeutics (PTGX) Operating Leases (2019 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Operating Leases for 8 years, with the latest figure at $7.4 million in Q1 2026.
- Quarterly Operating Leases fell 24.05% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 24.05% YoY) and the FY2025 annual result came in at $8.0 million, down 22.36% from the prior year.
- Operating Leases retreated to $7.4 million in Q1 2026 per PTGX's latest filing, from $8.0 million in the prior quarter.
- Over five years, Operating Leases peaked at $11.0 million in Q2 2024 and troughed at $462000.0 in Q1 2023.
- A 5-year average of $6.5 million and a median of $8.0 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2025: Operating Leases sank 84.91% in 2023, then retreated 17.0% in 2025.
- Over 5 years, Operating Leases stood at $1.1 million in 2022, then slumped by 59.51% to $462000.0 in 2023, then jumped by 2141.56% to $10.4 million in 2024, then retreated by 22.36% to $8.0 million in 2025, then declined by 7.5% to $7.4 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $7.4 million, $8.0 million, and $8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.82 Mn |
| Mar 31, 2026 | 7.44 Mn |
| Dec 31, 2025 | 8.04 Mn |
| Sep 30, 2025 | 8.52 Mn |
| Jun 30, 2025 | 9.11 Mn |
| Mar 31, 2025 | 9.79 Mn |
| Dec 31, 2024 | 10.36 Mn |
| Sep 30, 2024 | 10.86 Mn |
| Jun 30, 2024 | 10.97 Mn |
| Mar 31, 2023 | 462,000.00 |
| Dec 31, 2022 | 1.14 Mn |
| Sep 30, 2022 | 1.80 Mn |
| Jun 30, 2022 | 2.45 Mn |
| Mar 31, 2022 | 3.06 Mn |
| Dec 31, 2021 | 3.66 Mn |
| Sep 30, 2021 | 4.24 Mn |
| Jun 30, 2021 | 3.69 Mn |
| Mar 31, 2021 | 4.10 Mn |
| Dec 31, 2020 | 4.50 Mn |
| Sep 30, 2020 | 4.89 Mn |